Class / Patent application number | Description | Number of patent applications / Date published |
514180900 | Apoptosis affecting | 68 |
20100279947 | Modifications of apoptin - Phosphorylated Apoptin is described. Apoptin is tumor-specifically phosphorylated and part of the Apoptin apoptotic pathway in tumor cells is elucidated. New therapeutic possibilities, for example, novel therapeutic compounds that can work alone or, sequentially to, or jointly with other known compounds. Also, the use of tumor-specifically phosphorylation of Apoptin for diagnostic purposes is described. Such a diagnostic purpose can, for example, be a method for detecting the presence of cancer cells or cells that are cancer prone or a method to identify a putative cancer inducing agent or a method for the in vitro treatment effect of Apoptin on tumor cells by testing the phosphorylation state of Apoptin. Even more, the invention provides possibilities to further elucidate the apoptotic pathway and to identify for example crucial mediators of phosphorylation in human tumor cells. Interfering with such a mediator could provide new anti-cancer therapies. | 11-04-2010 |
20100279948 | EPIGENETIC MODIFICATIONS AT TNFalpha AS BIOMARKERS FOR SENSITIVITY TO SMAC MIMETIC-INDUCED APOPTOSIS - The invention provides a method for determining sensitivity of a cell population to apoptosis induced by Smac mimetics as a single agent or in combination with other chemodrugs, which method comprises assaying for an epigenetic modification at the TNFα locus in the cell population as compared to the TNFα locus in a cell population not sensitive to apoptosis induced by Smac mimetics as a single agent or in combination with other chemodrugs, wherein the presence of the epigenetic modification indicates that the cell population is sensitive to apoptosis induced by Smac mimetics as a single agent or in combination with other chemodrugs. | 11-04-2010 |
20100286057 | METHODS AND COMPOSITIONS FOR MODULATING BCL-2 FAMILY POLYPEPTIDES - The present invention is based, at least in part, on the identification of a novel active site on BCL-2 family polypeptide such as BAX, which when bound by a compound, modifies the activity of the BCL-2 family polypeptide. | 11-11-2010 |
20100317592 | CHEMOKINE-BINDING PROTEIN AND METHODS OF USE - Described herein are chemokine-binding domains of THAP-family polypeptides and pharmaceutical compositions which include a polypeptide comprising a chemokine-binding domain of a THAP-family polypeptide. Also disclosed are methods of binding chemokines, inhibiting the activity of chemokines, detecting chemokines, and reducing the symptoms associated with a chemokine mediated or influenced condition by contacting the chemokine with an agent that includes a polypeptide comprising a chemokine binding domain of a THAP-family polypeptide. | 12-16-2010 |
20100323968 | Process of inhibiting cell death in injured cartilage - Processes for inhibiting apoptotic cell death and glycosaminoglycan release from injured cartilage is provided. Inhibition is accomplished using caspase inhibitors. | 12-23-2010 |
20110034395 | COMPOSITIONS AND METHODS OF INHIBITING APOPTOSIS - A method of inhibiting apoptosis in a cell includes administering to a cell an effective amount of a cell penetrating peptide (CPP), wherein the CPP consists of about 5 to about 41 amino acids and is substantially homologous to a portion of the C-terminal region of IFNγR2. | 02-10-2011 |
20110046066 | INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula (I), and G, X | 02-24-2011 |
20110071089 | PEPTIDE COMPOSITION FOR CANCER TREATMENT BY INHIBITING TRPV6 CALCIUM CHANNEL ACTIVITY - The invention includes an isolated peptide comprising all or part of the amino acid sequence: EGKLSSNDTE GGLCKEFLHP SKVDLPR (SEQ ID NO: 1), wherein the peptide inhibits calcium channel activity. The peptides of the invention are useful for preventing or treating cancer. | 03-24-2011 |
20110092440 | METHOD OF REGULATING CELL GROWTH USING A PROTEASOME INHIBITOR - This invention provides methods and pharmaceutical compositions for regulating cell growth or inducing apoptosis in a cell, particularly a mammalian tumor cell. Specifically, the invention provides methods for inducing apoptosis in a tumor cell comprising contacting the tumor cell with a proteasome inhibitor and a thiazole antibiotic, particularly each in a suboptimal amount. | 04-21-2011 |
20110136743 | Survivin, a protein that inhibits cellular apoptosis, and its modulation - The present invention provides the amino acid of a protein that inhibits cellular apoptosis, herein termed the Survivin protein and nucleic acid molecules that encode Survivin. Based on this disclosure, the present invention provides isolated Survivin protein, isolated Survivin encoding nucleic acid molecules, methods of isolating other members of the Survivin family of proteins, methods for identifying agents that block Survivin mediated inhibition of cellular apoptosis, methods of using agents that block Survivin mediated inhibition or Survivin expression to modulate biological and pathological processes, and methods of assaying Survivin activity. | 06-09-2011 |
20110237517 | IAP INHIBITORS - The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy. | 09-29-2011 |
20110251134 | COMBINATION OF (A) A DNA TOPOSOMERASE INHIBITOR AND (B) AN IAP INHIBITOR - The invention relates to a pharmaceutical combination which comprises (a) a DNA topoisomerase inhibitor compound and (b) a compound that inhibits the caspase-9 inhibiting properties of an inhibitor of apoptosis protein (IAP) for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human. | 10-13-2011 |
20110263510 | Methods of Inhibiting Cell Death or Inflammation in a Mammal - Methods are provided for inhibiting cell death or inflammation in a mammal concurrent with or after the onset of a condition expected to lead to cell death or inflammation. The methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. Methods are also provided for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal concurrent with or after the onset of a condition expected to lead to cell death or inflammation. | 10-27-2011 |
20110263511 | TIGHT JUNCTION PROTEIN MODULATORS AND USES THEREOF - The invention provides tight junction protein modulators, compositions comprising the same, and uses thereof. In particular, the invention provides tight junction protein modulators that modulate the second extracellular loop of tight junction proteins, such as occludin or claudin. | 10-27-2011 |
20110269696 | INHIBITORS OF IAPS - The invention provides novel compounds that are inhibitors of IAPs having the general formula: wherein X | 11-03-2011 |
20110312896 | INHIBITORS OF BCL-2 - A purified polypeptide includes about 5 to about 80 amino acids and includes an amino acid sequence corresponding to a portion of SEQ ID NO:1. The polypeptide inhibiting binding of Bcl-2 to IP | 12-22-2011 |
20120035113 | METHODS OF REDUCING TRAIL-INDUCED APOPTOSIS BY TRAIL ISOFORMS - This document provides to methods and materials related to apoptosis. For example, methods and materials for modulating apoptosis are provided. In addition, methods and materials for treating a mammal having an apoptosis-associated condition are provided. | 02-09-2012 |
20120040913 | METHODS AND COMPOSITIONS FOR TREATING DIABETES - The instant invention provides a method of treating an animal suffering a disease characterized by excessive apoptosis by administering a therapeutically effective amount of at least one serine protease inhibitor and thereafter monitoring a decrease in apoptosis. The inhibitor of the invention includes α | 02-16-2012 |
20120058953 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS - The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same. | 03-08-2012 |
20120094922 | SCREENING ASSAYS FOR AGENTS THAT ALTER INHIBITOR OF APOPTOSIS (IAP) PROTEIN REGULATION OF CASPASE ACTIVITY - The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7 or a pro-caspase such as pro-caspase-9, or that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP. The invention further provides methods of reducing the severity of a pathologic condition in an individual by administering to the individual an agent that alters the caspase inhibitory activity of an IAP. | 04-19-2012 |
20120135938 | Polypeptides that Bind TRAIL-R1 and TRAIL-R2 - Agonists for TRAIL death receptors including polypeptides having a multimerizing, e.g. trimerizing, domain and a polypeptide sequence that binds to at least one of TRAIL death receptors TRAIL-R1 and TRAIL-R2. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin. The agonists can induce apoptosis in pathogenic cells expressing a TRAIL death receptor. Pharmaceutical compositions are described for treating diseases associated with cells expressing DR4 and DR5, such as tumor cells. Methods for selecting polypeptides and preparing multimeric complexes. | 05-31-2012 |
20120172310 | Soluble Guanylyl Cyclase a1 and a-8r Peptide as Diagnostic Markers of and Therapeutic Targets for Prostate Cancer - The present invention provides materials and methods useful to treat various sGCα1-expressing cancers. Materials include peptides which interfere with sGCα1's pro-survival functions, thereby resulting in apoptosis of sGCα1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits. | 07-05-2012 |
20120202747 | PHARMACEUTICAL COMPOSITION, FOOD OR DRINK, AND METHODS RELATED THERETO - A pharmaceutical composition including, as an active ingredient, one of the following proteins (I) and (II): (I) an apoptosis inhibitor of macrophage; and (II) a protein which consists of an amino acid sequence having deletion, substitution, or addition of one or more amino acids in an amino acid sequence of the apoptosis inhibitor of macrophage and having homology to the amino acid sequence of the apoptosis inhibitor of macrophage, and has a function of inhibiting the differentiation of preadipocytes to mature adipocytes and/or a function of inducing lipolysis in the mature adipocytes. | 08-09-2012 |
20120208767 | Method to Detect or Treat Painful Bladder Syndrome based on Relation to Quinone Oxidoreductase 1 - A method includes obtaining a biological sample from a subject that does not display a symptom of Painful Bladder Syndrome (PBS). The method also includes analyzing the biological sample for a mutated form of NAD(P)H dehydrogenase [quinone], also known as Quinone Oxidoreductase 1, abbreviated NQO1, or a mutation of a NQO1 gene. The method also includes determining a risk of PBS for the subject based on analyzing the biological sample. In some methods, the mutation determined to present an increased risk is a cytosine to thymine nucleotide substitution at a position that leads to a proline to serine amino acid substitution at amino acid position 187 to produce a protein NQO1P187S. Another method includes selecting a subject that has above normal risk of Painful Bladder Syndrome (PBS) or is expressing a symptom of PBS, and treating the subject with a therapeutically effective amount of an antioxidant. | 08-16-2012 |
20120225824 | MULLERIAN INHIBITING SUBSTANCE (MIS) ANALOGUES - Mullerian Inhibiting Substance analogues are disclosed which comprise one or more non-naturally occurring N-linked glycosylation sites, protease cleavage sites, and/or tags such as an epitope tag. Also disclosed are pharmaceutical compositions comprising such compositions and methods of using such compositions, for example in the treatment of conditions associated with uncontrolled growth of a tissue derived from a Mullerian duct, such as the condition endometriosis. | 09-06-2012 |
20130040892 | IAP BIR DOMAIN BINDING COMPOUNDS - A compound of Formula 1: (I) or salt thereof, as well as methods of making compounds of Formula 1, methods of using compounds of Formula 1 to treat proliferative disorders such as cancer, and related compounds, composition, and methods. | 02-14-2013 |
20130053328 | COMPOSITIONS AND METHODS OF INHIBITING PHOTORECEPTOR APOPTOSIS - The present invention provides compositions and methods to prevent apoptosis. In particular, provided herein are compositions and methods which prevent FAS-mediated photoreceptor apoptosis. | 02-28-2013 |
20130053329 | METHODS OF INHIBITING APOPTOSIS OR INFLAMMATION IN A MAMMAL BY ADMINISTERING AN ISOLATED BCL PROTEIN - In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal. | 02-28-2013 |
20130102541 | METHODS OF INHIBITING TUMOR CELL AGGRESSIVENESS USING THE MICROENVIRONMENT OF HUMAN EMBRYONIC STEM CELLS - The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and prevent tumor formation and progression and to inhibit tumor cell aggressiveness. The invention further provides methods of inhibiting tumor cell growth and/or treating aggressive tumors in a mammal comprising administering to the mammal, having at least one tumor cell present in its body, an effective amount of an inhibitor of Nodal activity. | 04-25-2013 |
20130123191 | METHODS OF INHIBITING PHOTORECEPTOR APOPTOSIS - The present invention provides methods to prevent photoreceptor death. In particular, the present invention provides peptides which prevent FAS-mediated photoreceptor apoptosis. | 05-16-2013 |
20130137642 | METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS - Provided are methods and compositions for maintaining the viability of photoreceptor cells and/or retinal pigment epithelial cells in a subject with an ocular disorder including, for example, age-related macular degeneration (AMD) (e.g., dry or neovascular AMD), retinitis pigmentosa (RP), or a retinal detachment. The viability of the photoreceptor cells and/or the retinal pigment epithelial cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells, thereby minimizing the loss of vision or visual function associated with the ocular disorder. | 05-30-2013 |
20130143823 | Compositions and methods of inhibiting apoptosis - A method of inhibiting apoptosis in a cell includes administering to a cell an effective amount of a cell penetrating peptide (CPP), wherein the CPP consists of about 5 to about 41 amino acids and is substantially homologous to a portion of the C-terminal region of IFNγR2. | 06-06-2013 |
20130172264 | INHIBITORS OF IAP - Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: | 07-04-2013 |
20130196927 | Smac Mimetic Therapy - A Smac mimetic therapy wherein the Smac mimetic is selected and developed based at least in part on its cIAP degradation properties. | 08-01-2013 |
20130217633 | INHIBITORS OF BCL-2 - A protease resistant polypeptide includes an amino acid sequence that has a sequence identity at least 80% homologous to about 10 to 80 consecutive amino acids of SEQ ID NO:1. | 08-22-2013 |
20130274198 | TREATING MUC1-EXPRESSING CANCERS WITH COMBINATION THERAPIES - The invention provides method of treating cancers that express MUC1 by the administration of PI3-K inhibitors in combination with MUC1-directed cancer therapies. The PI3-K inhibition may advantageously be combined with peptides that inhibit MUC1 oligomerization, or further with other standard anticancer therapies such as chemo-, radio- and surgical therapies. | 10-17-2013 |
20130274199 | Partial Fragment of REIC/Dkk-3 Gene and Cancer Therapeutic Agent Comprising the Same - This invention provides an inducer of apoptosis in cancer cells comprising a fragment of the REIC/Dkk-3 gene and a cancer therapeutic agent comprising the same. This invention also provides a polynucleotide fragment encoding the REIC/Dkk-3 protein (a) or (b), which encodes a polypeptide having apoptosis activity: (a) a polynucleotide encoding a polypeptide comprising an amino acid sequence of amino acid 1 to any of amino acids 39 to 78 of the amino acid sequence of the REIC/Dkk-3 protein as shown in SEQ ID NO: 2; or (b) a polynucleotide encoding a polypeptide comprising an amino acid sequence derived from the amino acid sequence of amino acid 1 to any of amino acids 39 to 78 of the amino acid sequence of the REIC/Dkk-3 protein as shown in SEQ ID NO: 2 by substitution, deletion, or addition of 1 or several amino acids and having apoptosis activity. | 10-17-2013 |
20130281381 | PHARMACEUTICAL COMPOSITIONS COMPRISING 8-SUBSTITUTED DIBENZYLBUTYROLACTONE LIGNANS - Therapeutic compositions comprising at least one 8-substituted-dibenzylbutyrolactone lignan, preferably a lignan is selected from the group of nortrachelogenin, diasteromeric forms of nortrachelogenin, isomeric forms of nortrachelogenin and combinations thereof as well as 8-methylmatairesinol and 8-methyldimethylmatairesinol, for use in a method of treating cancer or a similar condition wherein the growth factor signaling pathway of a mammal is deregulated. The invention also provides therapeutic pharmaceutical combinations comprising a hydroxy-dibenzylbutyrolactone lignan and at least one TRAIL receptor agonist. The hydroxy-dibenzylbutyrolactone lignans and a TRAIL receptor agonist can be used as a combined preparation for administration to a patient simultaneously, separately or spaced out over a period of time in treating cancer. | 10-24-2013 |
20130288979 | Inhibitors of Apoptosis and Uses Thereof - The invention relates to fragments of the DAXX and FADD proteins that inhibit cell apoptosis, in particular cell apoptosis mediated by the Fas receptor. The invention also relates to derivatives of said anti-apoptotic fragments, conjugates comprising said fragments, pharmaceutical compositions comprising said fragments, and to the medical applications of said fragments, derivatives, conjugates, and pharmaceutical compositions thereof in the treatment or prevention of diseases and conditions associated with apoptosis. | 10-31-2013 |
20130303460 | PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF NEUROECTODERMAL DERIVED TUMORS AND RETINOBLASTOMA - The present invention is directed to compositions and methods for the treatment of retinoblastoma and neuroectodermal derived tumors, such as primitive neuroectodermal tumors (PNET) and neuroblastoma. In particular, the present invention is directed to the use of 4F-benzoyl-TN14003 peptide or analogs or derivatives thereof for treating neuroblastoma and retinoblastoma. | 11-14-2013 |
20130316958 | HIGHLY POTENT PEPTIDES TO CONTROL CANCER AND NEURODEGENERATIVE DISEASES - This invention provides compositions and method of diminishing or inhibiting autophagy by administering a FLIP protein that binds to Atg3, interfering with the formation of the LC3-Atg4-Atg7-Atg3 conjugation complex necessary for autophagy induction. This invention also provides FLIP peptide fragments that promote or induce autophagy by interfering with the activity of FLIP. | 11-28-2013 |
20140045768 | Tight Junction Protein Modulators and Uses Thereof - The invention provides tight junction protein modulators, compositions comprising the same, and uses thereof. In particular, the invention provides tight junction protein modulators that modulate the second extracellular loop of tight junction proteins, such as occludin or claudin. | 02-13-2014 |
20140066382 | Autophagy-Inducing Peptide - An autophagy-inducing compound comprises an autophagy-inducing peptide comprising beclin-1 residues 269-283 and a heterologous moiety that promotes therapeutic stability or delivery of the compound. The compound may be used to induce autophagy and in assays with beclin-1 binding partners. | 03-06-2014 |
20140073578 | Combination Therapy with Leukotoxin - The invention relates to pharmaceutical compositions comprising leukotoxin, a chemotherapeutic agent and a pharmaceutically acceptable carrier, including methods to treat cancer, and methods to induce apoptosis. | 03-13-2014 |
20140073579 | SMAC Mimetic - A SMAC mimetic and pharmaceutical compositions thereof and methods of use. | 03-13-2014 |
20140121169 | Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis - A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps. | 05-01-2014 |
20140135270 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS - There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention. | 05-15-2014 |
20140155330 | Compositions And Methods For Modulating Apoptosis - Peptides, compositions and methods for modulating apoptosis, useful for treating diseases or disorders characterized by dysregulated apoptosis, such as cancer or neurodegenerative diseases. Screening methods for identifying agents that mediate apoptosis by regulating Atg12 binding to Bcl-2 family members. | 06-05-2014 |
20140171374 | USE OF A TRUNCATED EIF-5A1 POLYNUCLEOTIDE TO INDUCE APOPTOSIS IN CANCER CELLS - The present invention relates to the combinatorial use of an siRNA targeted against an endogenous gene to knock out or knock down expression of the endogenous gene in a host and a delivery of a polynucleotide encoding the gene in a delivery vehicle/expression vector to the host to provide expression in the host of the protein encoded by the polynucleotide. | 06-19-2014 |
20140179617 | Cytotoxic Factors For Modulating Cell Death - Cytotoxic factors having use in modulating cell death, and their use in methods of treating necrosis or apoptosis-related conditions are disclosed. The invention also relates to methods for identifying active agents useful in treating conditions related to cell death or uncontrolled growth. The present inventors have found that different microorganisms produce different cytotoxic factor(s) having anticancer activity. The substantially pure cytotoxic factors can be used in a method of treating an infectious disease or a cancer. | 06-26-2014 |
20140288006 | PTD-SMAD7 THERAPEUTICS - The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins. | 09-25-2014 |
20140303090 | Smac Mimetic Therapy - A Smac mimetic therapy wherein the Smac mimetic is selected and developed based at least in part on its poor inhibition of XIAP-dependent processes. | 10-09-2014 |
20140342993 | KINASE INHIBITORS AND USES THEREOF - The present invention relates to kinase inhibiting compositions and uses thereof. The invention further provides isolated kinase inhibiting peptides and uses thereof for inhibiting hyperplasia, for inhibiting the growth of neoplasms, and for inducing programmed cell death in a cell population. | 11-20-2014 |
20140371156 | MEMBRANE RESIDENT PEPTIDE IN ANTI-CANCER PEPTIDES CAUSES TUMOR CELL NECROSIS RATHER THAN APOPTOSIS OF CANCER CELLS - An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and administering to the cells a compound, including an HDM-2 targeting component and a cytotoxic component attached to the HDM-2 targeting component, wherein said compound comprises a membrane-active form. | 12-18-2014 |
20150018285 | ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS - The present invention provides an antagonist of a Bcl-2 pro survival protein containing a BH3-like domain. The antagonist of the invention comprises ARTS and any fragment or peptide that comprises a BH3-like domain. The invention further provides compositions, combined compositions and kits as well as methods for treating Bcl-2 over-expressing disorders. | 01-15-2015 |
20150045308 | Compositions and Methods of Treating Cancer - The present invention provides compositions and methods of treating various disorders associated with aberrant cell growth. | 02-12-2015 |
20150306168 | METHODS OF PROTECTING AGAINST APOPTOSIS USING LIPOPEPTIDES - The use of lipopeptides as inducers of NF-κB for the protection of mammals from the effects of apoptosis is described. | 10-29-2015 |
20150337010 | Method for treating or preventing liver related diseases - This invention discloses an isolated peptide containing an amino acid sequence of SEQ ID No.1. The isolated peptide is capable of providing the effects in suppressing hepatocyte apoptosis, attenuating hepatic triglyceride accumulation, suppressing the expression of inflammatory cytokines, inhibiting expression of pro-apoptotic proteins, enhancing expression of survival factor and inhibiting the expression of biomarker of hepatic fibrosis. Therefore, this invention discloses the peptide as the effective ingredient in a composition for treating or preventing liver related diseases. | 11-26-2015 |
20150376260 | Stable Form Of Signal Converting Protein Fusion Proteins, And Methods Of Use And Preparation Thereof - A stable fusion protein, wherein in solution, a majority of the fusion proteins are in the homo-hexamer form, which may be prepared for example as a CTLA4-FasL fusion protein. | 12-31-2015 |
20160038564 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS INVOLVING EPITHELIAL CELL APOPTOSIS - The present invention provides therapeutic and prophylactic compositions for use in treating and preventing disorders involved epithelial cell apoptosis, such as gastrointestinal disorders (e.g., inflammatory bowel disease, Crohn's disease or ulcerative colitis) in a subject, such as a human patient. | 02-11-2016 |
20160052965 | Dimeric IAP Inhibitors - Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language | 02-25-2016 |
20160082077 | FLAGELLIN RELATED POLYPEPTIDES AND USES THEREOF - The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptosis is described. | 03-24-2016 |
20160102119 | INHIBITORS OF IAP - Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: | 04-14-2016 |
20160108086 | PEPTIDE STIMULATOR OF CELL SURVIVAL AND PROLIFERATION - The invention provides a novel peptide, and derivatives thereof, which is stable in aqueous solution and which stimulates proliferation and survival of endothelial cells and/or fibroblasts. The present peptide can be used at least to promote the S phase of the cell cycle, to stimulate production of extracellular matrix proteins, to reduce apoptosis, to inhibit production of reactive oxygen species and/or to reduce or prevent damage to cell integrity or morphology under stress conditions of serum deprivation. | 04-21-2016 |
20160108100 | Interference Peptides and Use Thereof - A purified and isolated peptide comprises an amino acid sequence of SEQ ID NOs: 1 to 8. A method is also provided for preventing interaction, e.g. binding, of EN1 with EPRS in a cell by introducing, into the cell, a peptide having a sequence of SEQ ID NOs: 1 to 8, which results in the peptide interacting with EPRS thereby preventing an interaction of EPRS with EN1. Apoptosis can be induced in a cell expressing either or both of EN1 and EN2, by introducing into the cell, a peptide of SEQ ID NOs: 1 to 8. | 04-21-2016 |
20160176936 | MPS PEPTIDES AND USE THEREOF | 06-23-2016 |
20160376307 | IAP ANTAGONISTS - There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention. | 12-29-2016 |
20160376336 | NOVEL ENGINEERED POTENT CYTOTOXIC STAPLED BH3 PEPTIDES - Compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. Pharmaceutical compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. A method for treating cancer is provided. | 12-29-2016 |